133 related articles for article (PubMed ID: 37369013)
1. Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study.
Koyama T; Shimizu T; Kojima Y; Sudo K; Okuma HS; Shimoi T; Ichikawa H; Kohsaka S; Sadachi R; Hirakawa A; Yoshida A; Ando RM; Ueno T; Yanagaki M; Matsui N; Nakamura K; Yamamoto N; Yonemori K
Cancer Discov; 2023 Aug; 13(8):1814-1825. PubMed ID: 37369013
[TBL] [Abstract][Full Text] [Related]
2. Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study.
Takahashi S; Fujiwara Y; Nakano K; Shimizu T; Tomomatsu J; Koyama T; Ogura M; Tachibana M; Kakurai Y; Yamashita T; Sakajiri S; Yamamoto N
Cancer Sci; 2021 Jun; 112(6):2361-2370. PubMed ID: 33686772
[TBL] [Abstract][Full Text] [Related]
3. MDM2 dual-color in situ hybridization (DISH) aids the diagnosis of intimal sarcomas.
Jimbo N; Komatsu M; Itoh T; Hirose T
Cardiovasc Pathol; 2019; 43():107142. PubMed ID: 31442826
[TBL] [Abstract][Full Text] [Related]
4. A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas.
Gounder MM; Bauer TM; Schwartz GK; Weise AM; LoRusso P; Kumar P; Tao B; Hong Y; Patel P; Lu Y; Lesegretain A; Tirunagaru VG; Xu F; Doebele RC; Hong DS
J Clin Oncol; 2023 Mar; 41(9):1714-1724. PubMed ID: 36669146
[TBL] [Abstract][Full Text] [Related]
5. Primary cardiac undifferentiated pleomorphic sarcoma is associated with TP53 mutation during lack of MDM2 amplification, and targeted sequencing analysis reveals potentially actionable targets.
Cui Y; Han L; Shang J; Fang W; Zhao M; Chen D; Liu H
Hum Pathol; 2022 May; 123():113-122. PubMed ID: 35181378
[TBL] [Abstract][Full Text] [Related]
6. New targeted treatments for advanced sarcomas.
Li CC; Chen TW
Curr Opin Oncol; 2023 Jul; 35(4):309-314. PubMed ID: 37222206
[TBL] [Abstract][Full Text] [Related]
7. Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling.
Pishas KI; Neuhaus SJ; Clayer MT; Schreiber AW; Lawrence DM; Perugini M; Whitfield RJ; Farshid G; Manavis J; Chryssidis S; Mayo BJ; Haycox RC; Ho K; Brown MP; D'Andrea RJ; Evdokiou A; Thomas DM; Desai J; Callen DF; Neilsen PM
Cancer Res; 2014 Feb; 74(3):921-31. PubMed ID: 24336067
[TBL] [Abstract][Full Text] [Related]
8. MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status.
Flørenes VA; Maelandsmo GM; Forus A; Andreassen A; Myklebost O; Fodstad O
J Natl Cancer Inst; 1994 Sep; 86(17):1297-302. PubMed ID: 8064888
[TBL] [Abstract][Full Text] [Related]
9. Targeting MDM2 in Soft-Tissue Sarcomas (and Other Solid Tumors): The Revival?
Italiano A
Cancer Discov; 2023 Aug; 13(8):1765-1767. PubMed ID: 37539475
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive mapping of p53 pathway alterations reveals an apparent role for both SNP309 and MDM2 amplification in sarcomagenesis.
Ito M; Barys L; O'Reilly T; Young S; Gorbatcheva B; Monahan J; Zumstein-Mecker S; Choong PF; Dickinson I; Crowe P; Hemmings C; Desai J; Thomas DM; Lisztwan J
Clin Cancer Res; 2011 Feb; 17(3):416-26. PubMed ID: 21159888
[TBL] [Abstract][Full Text] [Related]
11. Intimal sarcomas and undifferentiated cardiac sarcomas carry mutually exclusive MDM2, MDM4, and CDK6 amplifications and share a common DNA methylation signature.
Koelsche C; Benhamida JK; Kommoss FKF; Stichel D; Jones DTW; Pfister SM; Heilig CE; Fröhling S; Stenzinger A; Buslei R; Mentzel T; Baumhoer D; Ladanyi M; Antonescu CR; Flucke U; Gorp JV; Bode-Lesniewska B; Deimling AV; Mechtersheimer G
Mod Pathol; 2021 Dec; 34(12):2122-2129. PubMed ID: 34312479
[TBL] [Abstract][Full Text] [Related]
12. Automated brightfield dual-color in situ hybridization for detection of mouse double minute 2 gene amplification in sarcomas.
Zhang W; McElhinny A; Nielsen A; Wang M; Miller M; Singh S; Rueger R; Rubin BP; Wang Z; Tubbs RR; Nagle RB; Roche P; Wu P; Pestic-Dragovich L
Appl Immunohistochem Mol Morphol; 2011 Jan; 19(1):54-61. PubMed ID: 20881839
[TBL] [Abstract][Full Text] [Related]
13. Primary cardiac sarcomas: A clinicopathologic study in a single institution with 25 years of experience with an emphasis on MDM2 expression and adjuvant therapy for prognosis.
Cho H; Song IH; Jo U; Jeong JS; Koo HJ; Yang DH; Jung SH; Song JS; Cho KJ
Cancer Med; 2023 Aug; 12(16):16815-16828. PubMed ID: 37395142
[TBL] [Abstract][Full Text] [Related]
14. Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma.
Ohnstad HO; Castro R; Sun J; Heintz KM; Vassilev LT; Bjerkehagen B; Kresse SH; Meza-Zepeda LA; Myklebost O
Cancer; 2013 Mar; 119(5):1013-22. PubMed ID: 23165797
[TBL] [Abstract][Full Text] [Related]
15. Cardiac intimal sarcoma with PDGFRβ mutation and co-amplification of PDGFRα and MDM2: an autopsy case analyzed by whole-exome sequencing.
Ito Y; Maeda D; Yoshida M; Yoshida A; Kudo-Asabe Y; Nanjyo H; Izumi C; Yamamoto F; Inoue M; Shibata H; Katoh H; Ishikawa S; Nakamura H; Totoki Y; Shibata T; Yachida S; Goto A
Virchows Arch; 2017 Sep; 471(3):423-428. PubMed ID: 28474091
[No Abstract] [Full Text] [Related]
16. Intimal Sarcoma with MDM2/CDK4 Amplification and p16 Overexpression: A Review of Histological Features in Primary Tumor and Xenograft, with Immunophenotype and Molecular Profiling.
Giner F; Machado I; Rubio-Martínez LA; López-Guerrero JA; Claramunt-Alonso R; Navarro S; Ferrández A; Mayordomo-Aranda E; Llombart-Bosch A
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108696
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification.
Cornillie J; Wozniak A; Li H; Gebreyohannes YK; Wellens J; Hompes D; Debiec-Rychter M; Sciot R; Schöffski P
Clin Transl Oncol; 2020 Apr; 22(4):546-554. PubMed ID: 31201607
[TBL] [Abstract][Full Text] [Related]
18. The protooncogene CHOP/GADD153, involved in growth arrest and DNA damage response, is amplified in a subset of human sarcomas.
Forus A; Flørenes VA; Maelandsmo GM; Fodstad O; Myklebost O
Cancer Genet Cytogenet; 1994 Dec; 78(2):165-71. PubMed ID: 7828148
[TBL] [Abstract][Full Text] [Related]
19. Loss of heterozygosity at 12q14-15 often occurs in stage I soft tissue sarcomas and is associated with MDM2 amplification in tumors at various stages.
Taubert H; Schuster K; Brinck U; Bartel F; Kappler M; Lautenschläger C; Bache M; Trump C; Schmidt H; Holzhausen HJ; Würl P; Schlott T
Mod Pathol; 2003 Nov; 16(11):1109-16. PubMed ID: 14614050
[TBL] [Abstract][Full Text] [Related]
20. Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network.
Frezza AM; Assi T; Lo Vullo S; Ben-Ami E; Dufresne A; Yonemori K; Noguchi E; Siontis B; Ferraro R; Teterycz P; Duffaud F; Ravi V; Vincenzi B; Gelderblom H; Pantaleo MA; Baldi GG; Desar I; Fedenko A; Maki RG; Jones RL; Benjamin RS; Blay JY; Kawai A; Gounder M; Gronchi A; Le Cesne A; Mir O; Czarnecka AM; Schuetze S; Wagner AJ; Adam J; Barisella M; Sbaraglia M; Hornick JL; Meurgey A; Mariani L; Casali PG; Thornton K; Stacchiotti S
Cancer; 2020 Jan; 126(1):98-104. PubMed ID: 31536651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
